Canaccord Genuity Downgrades Xylem (XYL) to Hold

Go back to Canaccord Genuity Downgrades Xylem (XYL) to Hold

DA Davidson Downgrades Xylem (XYL) to Underperform

July 31, 2013 2:37 PM EDT

DA Davidson downgraded Xylem (NYSE: XYL) from Neutral to Underperform with a price target of $23.00 (from $28.00).

For an analyst ratings summary and ratings history on Xylem click here. For more ratings news on Xylem click here.

Shares of Xylem closed at $25.54 yesterday, with a 52 week range of $22.43-$29.79.... More

Wedbush Downgrades Xylem (XYL) to Neutral

July 31, 2013 6:56 AM EDT

Wedbush downgraded Xylem (NYSE: XYL) from Outperform to Neutral with a price target of $27.00 (from $32.00).

For an analyst ratings summary and ratings history on Xylem click here. For more ratings news on Xylem click here.

Shares of Xylem closed at $25.54 yesterday, with a 52 week range of $22.43-$29.79.... More

Atlantic Equities Downgrades Xylem (XYL) to Neutral

July 31, 2013 6:55 AM EDT

Atlantic Equities downgraded Xylem (NYSE: XYL) from Overweight to Neutral.

For an analyst ratings summary and ratings history on Xylem click here. For more ratings news on Xylem click here.

Shares of Xylem closed at $25.54 yesterday, with a 52 week range of $22.43-$29.79.... More

BB&T Capital Downgrades Xylem (XYL) to Hold

July 30, 2013 1:28 PM EDT

BB&T Capital downgraded Xylem (NYSE: XYL) from Buy to Hold.

For an analyst ratings summary and ratings history on Xylem click here. For more ratings news on Xylem click here.

Shares of Xylem closed at $28.46 yesterday, with a 52 week range of $22.43-$29.79.... More

Brean Capital Downgrades Xylem (XYL) to Hold

July 30, 2013 9:09 AM EDT

Brean Capital downgraded Xylem (NYSE: XYL) from Buy to Hold. The downgrade follows disappointing Q2 results.

"Xylem's 2Q13 EPS results and 2013 guidance revisions have changed our investment thesis on the name. Adjusted EPS of $0.36 was well below consensus of $0.44, and the new full... More

Xylem, Inc. (XYL) Misses Q2 EPS by 8c; Trims FY13 EPS Views

July 30, 2013 7:18 AM EDT

Xylem, Inc. (NYSE: XYL) reported Q2 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $960 million versus the consensus estimate of $967.9 million.

Sees FY2013 EPS of $1.40-$1.50, versus prior guidance of $1.79-$1.89 and the consensus of $1.82. Sees... More